Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GRN | P28799 | 4/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL1013112 | 0.90 | GRN (0.44) | KDM4EGRNSORT1CNR1CNR2 | |
| SCHEMBL283910 | 0.85 | KDM4E (0.44) | KDM4EGRNSORT1ADORA2AADORA2B | |
| SCHEMBL16564299 | 0.82 | MPO (0.42) | KDM4EADORA2AADORA2BPOLBALDH1A1 | |
| SCHEMBL282922 | 0.82 | CNR1 (0.49) | KDM4EGRNSORT1CNR1CNR2 | |
| SCHEMBL284028 | 0.80 | CNR1 (0.55) | KDM4ECNR1CNR2 | |
| SCHEMBL1924672 | 0.79 | KDM4E (0.42) | KDM4EGRNSORT1CNR1CNR2 | |
| SCHEMBL15069908 | 0.79 | KDM4E (0.42) | KDM4EGRNSORT1CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL1011856 | 0.78 | KDM4E (0.41) | KDM4EGRNSORT1CNR1CNR2 | |
| SCHEMBL22505758 | 0.78 | KDM4E (0.41) | KDM4EGRNSORT1CNR1CNR2 | |
| SCHEMBL283439 | 0.78 | KDM4E (0.41) | KDM4EGRNSORT1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| CN-110049969-A | Quinolines, preparation method and its medical usage | 恩瑞生物医药科技（上海）有限公司 | 2019-07-23 | — | — | CN | disclosed |
| EP-3004098-B1 | KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2017-08-09 | — | — | EP | disclosed |
| US-9403815-B2 | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403815-B2 | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403815-B2 | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-9359354-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-07 | — | — | US | disclosed |
| EP-3004098-A1 | KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2016-04-13 | — | — | EP | disclosed |
| US-20140364411-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | US | disclosed |
| WO-2014195400-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-11 | — | — | WO | disclosed |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-06-27 | — | — | US | disclosed |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-06-27 | — | — | US | disclosed |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-06-27 | — | — | US | disclosed |
| EP-2585455-A2 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | The Regents of The University of California (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011163636-A2 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-1761520-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364411-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | KDM4E 4675/4885GRN 3926/4885SORT1 4558/4885 |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | IAPP, APP, BACE1 | KDM4E 4398/4885GRN 36/4885SORT1 188/4885 |
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | WEE2, WEE1, HASPIN | KDM4E 3145/4885GRN 4744/4885SORT1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.